CLTR COULTER PHARMACEUTICAL Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (221)	6/17/1999 3:15:00 PM
From: Vector1	Read Replies (1) of 666

LOL, I tried to get some info from their Web Site but there was not much there. Interestingly in the Job opportunity section having worked on wall street was a disqualifying credential. Gee, wouldn't want someone with experience. I do not know who these guys are but they are way off base on CLTR. Yes CLTR more than hinted that they would do a rolling filing commenced in the first quarter, but if they make a complete filing by June 30 and still get fast track then no big deal. My understanding of the reason for the delay was manufacturing. CLTR will outsource both the MAB and the radioisotope. To a large degree the manufacturing in is out of their control and Nordian and Ampersham may not have their sense of urgency. I am told that the clinical portion of the filing has been done for over a month. I have yet to hear a cogent argument as to why from an efficacy standpoint Bexxar will not be approved. Once approved Bexxar will be a $100m drug in year one growing IMO to in excess of $300m. With ample cash and a strong partner CLTR is the best one year risk reward play in the sector. V1

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next